Stock 6483 ORIGINAL BIOMEDICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Original BioMedicals Co., Ltd.

Equities

6483

TW0006483001

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
14.55 TWD -2.02% Intraday chart for Original BioMedicals Co., Ltd. -6.73% -19.61%
09/04 Original BioMedicals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 432.8 432.8 519.5 851.6 851.6 1,186
Enterprise Value (EV) 1 406.9 436.3 535 789 822.6 874.2
P/E ratio -6.18 x -11.5 x -14.4 x -22.2 x -21 x -15 x
Yield - - - - - -
Capitalization / Revenue 126 x - - - 7,959 x 27,592 x
EV / Revenue 118 x - - - 7,688 x 20,331 x
EV / EBITDA -6.75 x -15.3 x -21.2 x -28.8 x -23.1 x -16 x
EV / FCF -8.7 x -24.3 x -48.1 x -55.5 x -50.1 x -113 x
FCF Yield -11.5% -4.12% -2.08% -1.8% -2% -0.89%
Price to Book 5.71 x 8.23 x 13.7 x 7.81 x 12.3 x 3.61 x
Nbr of stocks (in thousands) 23,910 23,910 28,700 47,050 47,050 65,550
Reference price 2 18.10 18.10 18.10 18.10 18.10 18.10
Announcement Date 28/03/19 23/03/20 27/01/21 21/06/22 27/03/23 09/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3.441 - - - 0.107 0.043
EBITDA 1 -60.24 -28.59 -25.26 -27.42 -35.64 -54.64
EBIT 1 -71.29 -38.94 -33.74 -32.66 -40.18 -59.26
Operating Margin -2,071.9% - - - -37,547.66% -1,37,818.6%
Earnings before Tax (EBT) 1 -70.06 -37.65 -34.75 -33.88 -40.28 -59.66
Net income 1 -70.06 -37.65 -34.75 -33.88 -40.28 -59.66
Net margin -2,036.12% - - - -37,642.06% -1,38,746.51%
EPS 2 -2.930 -1.574 -1.260 -0.8140 -0.8600 -1.210
Free Cash Flow 1 -46.79 -17.96 -11.11 -14.23 -16.41 -7.746
FCF margin -1,359.64% - - - -15,337.85% -18,014.83%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 28/03/19 23/03/20 27/01/21 21/06/22 27/03/23 09/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 3.57 15.5 - - -
Net Cash position 1 25.9 - - 62.7 29 312
Leverage (Debt/EBITDA) - -0.1249 x -0.6142 x - - -
Free Cash Flow 1 -46.8 -18 -11.1 -14.2 -16.4 -7.75
ROE (net income / shareholders' equity) -63.9% -55.3% -70.6% -46.1% -45.2% -30%
ROA (Net income/ Total Assets) -34.7% -26.5% -26.2% -19.9% -21.3% -15.8%
Assets 1 201.7 142 132.9 169.9 188.8 377.5
Book Value Per Share 2 3.170 2.200 1.320 2.320 1.470 5.010
Cash Flow per Share 2 1.080 0.8300 0.2800 0.1800 0.3000 3.490
Capex 1 5.93 - - 1.92 0.47 0.31
Capex / Sales 172.3% - - - 436.45% 723.26%
Announcement Date 28/03/19 23/03/20 27/01/21 21/06/22 27/03/23 09/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ORIGINAL BIOMEDICALS CO., LTD. Stock Original BioMedicals Co., Ltd.
-19.61% 29.33M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6483 Stock
  4. Financials Original BioMedicals Co., Ltd.